Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 5/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392348 | 0.91 | SSTR3 (0.53) | KMT2APOLBALDH1A1SSTR3F10 | |
| SCHEMBL14368821 | 0.91 | SSTR3 (0.53) | KMT2APOLBALDH1A1SSTR3F10 | |
| SCHEMBL14368693 | 0.91 | KMT2A (0.55) | KMT2APOLBALDH1A1HPGDSSTR3 | |
| SCHEMBL14392349 | 0.91 | KMT2A (0.55) | KMT2APOLBALDH1A1HPGDSSTR3 | |
| SCHEMBL14392690 | 0.90 | SSTR3 (0.50) | KMT2APOLBALDH1A1SSTR3F10 | |
| SCHEMBL14368825 | 0.90 | SSTR3 (0.50) | KMT2APOLBALDH1A1SSTR3F10 | |
| SCHEMBL5662592 | 0.89 | HRH3 (0.52) | KMT2AALDH1A1HPGDHRH3 | |
| SCHEMBL27757464 | 0.89 | HRH3 (0.52) | KMT2AALDH1A1HPGDHRH3 | |
| SCHEMBL14368968 | 0.88 | TSHR (0.52) | KMT2AALDH1A1SSTR3SMN1; SMN2F10 | |
| SCHEMBL4552939 | 0.88 | TSHR (0.52) | KMT2AALDH1A1SSTR3SMN1; SMN2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | KMT2A 3736/4885POLB 4668/4885ALDH1A1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.